Drugs / Glycyrrhizin
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06291623 | May 2022 → Dec 2023 | dental pulp necrosis | Mansoura University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06378346 | Jul 2024 → Mar 2027 expected | prostate cancer | University of Illinois at Chicago | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07236567 | Dec 2025 → Oct 2027 expected | dental pulp necrosis | Al-Azhar University | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02651350 Background | Dec 2015 → Jul 2019 | drug-induced liver injury | Beijing 302 Hospital | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06453304 Comparator | Mar 2022 → Jun 2024 | — | Mansoura University | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02331745 Background | Oct 2013 → Apr 2016 | alcoholic liver disease, hepatitis B virus infection, liver failure | Beijing 302 Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glycyrrhizin | “Glycyrrhizin (an oleanane-type triterpenoid glucuronide), the main active and important constituent in licorice, is 50 times sweeter than sugar (29) and is used in large...” NCT06453304 ↗5“Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission.” NCT02331745 ↗ “including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA)” NCT02651350 ↗ |
| Known as | Gly | “This study aimed to assess and compare the antibacterial effectiveness of glycyrrhizin (Gly) and calcium hydroxide (Ca(OH)2) as intracanal medicaments using molecular analysis.” PMID 41814304 ↗ Mar 20261“one cycle of therapy consisting of Glycyrrhizin (GLY) (Observation, Dose Level 1 75mg daily, or Dose Level 2, 150mg daily) for 5 weeks (+/- 2 weeks) prior to surgery.” NCT06378346 ↗ |
| Route | Oral | “75 mg orally daily” NCT06378346 ↗ |